IDEAS home Printed from https://ideas.repec.org/a/gam/jijerp/v15y2018i9p1799-d164936.html
   My bibliography  Save this article

Therapeutic Schedule Evaluation for Brain-Metastasized Non-Small Cell Lung Cancer with A Probabilistic Linguistic ELECTRE II Method

Author

Listed:
  • Ling Pan

    (Business School, Sichuan University, Chengdu 610064, China)

  • Peijia Ren

    (Business School, Sichuan University, Chengdu 610064, China)

  • Zeshui Xu

    (Business School, Sichuan University, Chengdu 610064, China
    School of Computer and Software, Nanjing University of Information Science and Technology, Nanjing 210044, China)

Abstract

With the rapid development of modern medicine, therapeutic schedules of brain-metastasized non-small cell lung cancer (NSCLC) are expanding. To assist a patient who suffers from brain-metastasized NSCLC to select the most suitable therapeutic schedule, firstly, we establish an indicator system for evaluating the therapeutic schedules; then, we propose a probabilistic linguistic ELECTRE II method to handle the corresponding evaluation problem for the following reasons: (1) probabilistic linguistic information is effective to depict the uncertainty of the therapeutic process and the fuzziness of an expert’s cognition; (2) the ELECTRE II method can deal with evaluation indicators that do not meet a fully compensatory relationship. Simulation tests on the parameters in the proposed method are provided to discuss their impacts on the final rankings. Furthermore, we apply the proposed method to help a patient with brain-metastasized NSCLC at the Sichuan Cancer Hospital and Institute to choose the optimal therapeutic schedule, and we present some sensitive analyses and comparative analyses to demonstrate the stability and applicability of the proposed method.

Suggested Citation

  • Ling Pan & Peijia Ren & Zeshui Xu, 2018. "Therapeutic Schedule Evaluation for Brain-Metastasized Non-Small Cell Lung Cancer with A Probabilistic Linguistic ELECTRE II Method," IJERPH, MDPI, vol. 15(9), pages 1-23, August.
    • Handle: RePEc:gam:jijerp:v:15:y:2018:i:9:p:1799-:d:164936
    as

    Download full text from publisher

    File URL: https://www.mdpi.com/1660-4601/15/9/1799/pdf
    Download Restriction: no
    File URL: https://www.mdpi.com/1660-4601/15/9/1799/
    Download Restriction: no
    ---><---

    References listed on IDEAS

    as
    1. Chunxiang Zhang & Hongmei Zhang & Jinning Shi & Dong Wang & Xiuwei Zhang & Jian Yang & Qizhi Zhai & Aixia Ma, 2016. "Trial-Based Cost-Utility Analysis of Icotinib versus Gefitinib as Second-Line Therapy for Advanced Non-Small Cell Lung Cancer in China," PLOS ONE, Public Library of Science, vol. 11(3), pages 1-10, March.
    2. Eun-A Lim & Haeyoung Lee & Eunmi Bae & Jaeok Lim & Young Kee Shin & Sang-Eun Choi, 2016. "Economic Evaluation of Companion Diagnostic Testing for EGFR Mutations and First-Line Targeted Therapy in Advanced Non-Small Cell Lung Cancer Patients in South Korea," PLOS ONE, Public Library of Science, vol. 11(8), pages 1-14, August.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Ameeth Sooklall & Jean Vincent Fonou-Dombeu, 2022. "An Enhanced ELECTRE II Method for Multi-Attribute Ontology Ranking with Z-Numbers and Probabilistic Linguistic Term Set," Future Internet, MDPI, vol. 14(10), pages 1-36, September.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Miriam Kasztura & Aude Richard & Nefti-Eboni Bempong & Dejan Loncar & Antoine Flahault, 2019. "Cost-effectiveness of precision medicine: a scoping review," International Journal of Public Health, Springer;Swiss School of Public Health (SSPH+), vol. 64(9), pages 1261-1271, December.
    2. Szu-Chun Yang & Wu-Wei Lai & Jason C Hsu & Wu-Chou Su & Jung-Der Wang, 2020. "Comparative effectiveness and cost-effectiveness of three first-line EGFR-tyrosine kinase inhibitors: Analysis of real-world data in a tertiary hospital in Taiwan," PLOS ONE, Public Library of Science, vol. 15(4), pages 1-13, April.

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:gam:jijerp:v:15:y:2018:i:9:p:1799-:d:164936. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: MDPI Indexing Manager (email available below). General contact details of provider: https://www.mdpi.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.